
    
      Patients will be randomized to 1 of 4 groups: placebo, pulsed albuterol, oxandrolone, or both
      pulsed albuterol and oxandrolone. Treatment will continue for 52 weeks unless unacceptable
      side effects occur. Patients will undergo testing of muscle function. All patients will
      return for follow-up assessments at Weeks 4, 12, 26, and 52.
    
  